Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.
Nikolai Podoltsev, MD, PhD
Advertisement
Nikolai Podoltsev, MD, PhD, is an associate professor of internal medicine (hematology); Duffy Firm Chief for Education, Department of Internal Medicine; associate director, Hematology/Oncology Fellowship Program, Department of Internal Medicine; clinical director, Malignant Hematology, Department of Internal Medicine, Division of Malignant Hematology, Yale Cancer Center.
Articles by Nikolai Podoltsev, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5